أعرض في EDS

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

التفاصيل البيبلوغرافية
العنوان: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
المؤلفون: Liwei Wang, Lu Zou, Xuya Cui, Xiangsong Wu, Xiaoling Song, Yidi Zhu, Xuechuan Li, Wan Yee Lau, Maolan Li, Wei Gong, Tai Ren, Jiujie Cui, Huaifeng Li, Yingbin Liu, Wenguang Wu, Xu-Sheng Han, Xu-An Wang
المصدر: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
سنة النشر: 2020
مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, FOLFIRINOX, medicine.medical_treatment, Leucovorin, GemOx, Irinotecan, Deoxycytidine, Cholangiocarcinoma, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Humans, Progression-free survival, RC254-282, Aged, Retrospective Studies, Chemotherapy, business.industry, Incidence (epidemiology), Research, mFOLFIRINOX chemotherapy gemcitabine cholangiocarcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Gemcitabine, Oxaliplatin, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Folfirinox Regimen, Fluorouracil, business, medicine.drug
الوصف: Background Gemcitabine plus platinum as the first-line chemotherapy for cholangiocarcinoma (CCA) has limited efficacy. The aim of this study was to evaluate the effectiveness of modified FOLFIRINOX (mFOLFIRINOX) compared to that of gemcitabine plus oxaliplatin (Gemox) for patients with locally advanced or metastatic CCA. Methods From January 2016 to December 2019, consecutive patients who were diagnosed with locally advanced or metastatic CCA were treated with either mFOLFIRINOX or Gemox as a first-line chemotherapy. The main endpoint was Progression free survival (PFS). The second endpoints were Overall survival (OS), Disease control rate (DCR) and incidence of severe toxicity (grade 3–4). Tumors were evaluated at baseline and thence every 4–6 weeks. The study was designed and carried out in accordance with the principles of the declaration of Helsinki, approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine (XHEC-D-2020-154) and registered with ClinicalTrials.gov, number NCT04305288 (registration date: 12/03/2020). Results Of 49 patients in this study, 27 were in the FOLFIRINOX regimen group and 22 in the Gemox regimen group. There were no significant differences between groups in baseline characteristics. The DCR was 77.8% in the mFOLFIRINOX group and 63.5% in the Gemox group. The corresponding median PFS was 9.9 months (95% confidence interval [CI], 7.3–12.4) in the mFOLFIRINOX group versus 6.4 months (95% CI,3.6–9.2, p = 0.040) in the Gemox group. The corresponding median OS was 15.7 months (95% CI, 12.5–19.0) versus 12.0 months (95% CI, 9.3–14.8, p = 0.099). Significantly more grade 3–4 vomiting occurred in the mFOLFIRINOX than the Gemox groups (7 (25.9%) vs 1 (4.5%), p = 0.044). Conclusions First-line mFOLFIRINOX offered more promising results in patients with advanced or metastatic CCA.
تدمد: 1471-2407
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80a0b6bb2d2cf8c59bad13dd8e7dc4f5
https://pubmed.ncbi.nlm.nih.gov/34266407
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....80a0b6bb2d2cf8c59bad13dd8e7dc4f5
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14712407